MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-07-2026
RedHill Biopharma Ltd. Total Liabilities 2011-2026 | RDHL
Annual Total Liabilities RedHill Biopharma Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.7 M | 21 M | 207 M | 172 M | 166 M | 14.1 M | 11.2 M | 12.3 M | 11.5 M | 6.75 M | 3.84 M | 2.42 M | 1.08 M | 1.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 207 M | 1.08 M | 46.7 M |
Quarterly Total Liabilities RedHill Biopharma Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 172 M | - | 174 M | - | 166 M | - | 132 M | - | 14.1 M | - | 17.8 M | - | 11.2 M | - | 11.9 M | - | 12.3 M | - | - | - | 11.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 174 M | 11.2 M | 72.3 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
390 M | $ 3.55 | -0.42 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
119 M | $ 3.25 | 3.83 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
7.8 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptorum Group Limited
APM
|
4.35 M | $ 0.79 | 0.03 % | $ 4.31 M | China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
440 M | $ 4.12 | -1.9 % | $ 105 M | Schweiz |
 |
Arcturus Therapeutics Holdings
ARCT
|
57.2 M | $ 6.55 | -1.28 % | $ 179 M |  Israel |
 |
argenx SE
ARGX
|
704 M | $ 709.08 | 0.82 % | $ 25 B |  Niderland |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.43 | -4.99 % | $ 8.25 B |  Australia |
 |
Ascendis Pharma A/S
ASND
|
1.47 B | $ 229.99 | -0.45 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
39.8 M | $ 6.09 | 0.58 % | $ 496 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
28.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
BioCardia
BCDA
|
4.59 M | $ 1.29 | 1.24 % | $ 27.3 M | USA |
 |
Anika Therapeutics
ANIK
|
42.3 M | $ 14.55 | 1.32 % | $ 213 M | USA |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aptose Biosciences
APTO
|
14.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
59.5 M | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.62 | -0.75 % | $ 16.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
355 M | $ 1.51 | - | $ 385 M | Britain |
 |
Athira Pharma
ATHA
|
13.9 M | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
2.76 B | $ 94.12 | 3.95 % | $ 27.2 B | Germany |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 8.27 | 2.54 % | $ 1.34 B | Britain |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 3.5 | -2.51 % | $ 7.62 B | Israel |